StemCyte International, Ltd. (TPEX:4178)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
27.60
-0.15 (-0.54%)
At close: Feb 26, 2026
-23.97%
Market Cap 5.31B
Revenue (ttm) 385.12M
Net Income (ttm) -187.63M
Shares Out 192.24M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 406,741
Average Volume 267,964
Open 27.35
Previous Close 27.75
Day's Range 26.85 - 28.20
52-Week Range 20.50 - 37.40
Beta n/a
RSI 33.31
Earnings Date Apr 29, 2026

About StemCyte International

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation and storage services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disord... [Read more]

Industry Miscellaneous Health And Allied Services, Not Elsewhere Classified
Founded 1997
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4178
Full Company Profile

Financial Performance

In 2024, StemCyte International's revenue was 382.69 million, an increase of 5.49% compared to the previous year's 362.78 million. Losses were -205.66 million, -35.68% less than in 2023.

Financial Statements

News

There is no news available yet.